

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Vassilios PAPADOPOULOS, et al.

Application No. 09/047,652

Filed: March 25, 1998

For: PERIPHERAL-TYPE BENZODIAZEPINE
RECEPTOR: A TOOL FOR DETECTION,
DIAGNOSIS, PROGNOSIS, AND
TREATMENT OF HUMAN BREAST
CANCER



Group Art Unit: 1642

Examiner: M. Davis

15/108
SUGP
11/2/00

REPLY AND AMENDMENTS PURSUANT TO 37 C.F.R. §§ 1.111 AND 1.115

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action [non-final rejection] mailed on April 12, 2000, kindly
amend the above-identified application as follows:

IN THE CLAIMS:

Kindly cancel claims 48-52 and substitute the following claims therefor.

DI

--53. An isolated, biologically pure antisense oligonucleotide that possesses a
complementary structure to at least a portion of the peripheral-type benzodiazepine receptor
(PBR) are having the nucleic acid sequence contained in SEQ ID NO: 1 or SEQ ID NO: 2
wherein said oligonucleotide, when introduced into a cell line that expresses said PBR gene
inhibits the expression thereof, and thereby inhibits proliferation of said cell line relative to
an otherwise identical cell line which does not comprise said antisense oligonucleotide.

54. The antisense oligonucleotide of claim 53, which possesses a complementary
structure to at least a portion of the nucleic acid sequence contained in SEQ ID NO: 1.